ADILW
Income statement / Annual
Last year (2023), Adial Pharmaceuticals, Inc. WT EXP 073123's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Adial Pharmaceuticals, Inc. WT EXP 073123's net income was -$7.00 M.
See Adial Pharmaceuticals, Inc. WT EXP 073123’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$564.00 |
$60,501.00 |
$55,106.00 |
$564.00 |
$565.00 |
$563.00 |
$565.00 |
$565.00 |
$565.00 |
| Gross Profit |
-$564.00 |
-$60,501.00 |
-$55,106.00 |
-$564.00 |
-$565.00 |
-$563.00 |
-$565.00 |
-$565.00 |
-$565.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$1.27 M
|
$4.18 M
|
$8.40 M
|
$5.85 M
|
$3.97 M
|
$368,459.00
|
$182,107.00
|
$146,143.00
|
$322,107.00
|
| General & Administrative
Expenses |
$5.62 M
|
$9.14 M
|
$9.34 M
|
$5.07 M
|
$4.28 M
|
$6.62 M
|
$813,179.00
|
$264,664.00
|
$497,150.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.62 M
|
$9.14 M
|
$9.34 M
|
$5.07 M
|
$4.28 M
|
$6.62 M
|
$813,179.00
|
$264,664.00
|
$497,150.00
|
| Other Expenses |
$0.00 |
$0.00 |
$46,494.00 |
$2,500.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$6.89 M |
$13.32 M |
$17.74 M |
$10.93 M |
$8.24 M |
$6.99 M |
$995,286.00 |
$410,807.00 |
$819,257.00 |
| Cost And Expenses |
$6.89 M |
$13.32 M |
$17.74 M |
$10.93 M |
$8.24 M |
$6.99 M |
$995,286.00 |
$410,807.00 |
$819,257.00 |
| Interest Income |
$69,779.00 |
$63,338.00 |
$6,539.00 |
$32,495.00 |
$95,234.00 |
$7,392.00 |
$367.00 |
$240.00 |
$1,264.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.17 M |
$144,537.00 |
$9,643.00 |
$0.00 |
| Depreciation &
Amortization |
$564.00
|
$564.00
|
$55,106.00
|
$564.00
|
$565.00
|
$563.00
|
$565.00
|
$565.00
|
$565.00
|
| EBITDA |
-$7.00 M
|
-$13.32 M
|
-$19.46 M
|
-$10.93 M
|
-$8.15 M
|
-$6.98 M
|
-$994,354.00
|
-$410,002.00
|
-$817,428.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$113,943.00
|
$585,209.00
|
-$1.82 M
|
$34,995.00
|
-$346,529.00
|
-$4.64 M
|
-$144,170.00
|
-$9,393.00
|
$1,264.00
|
| Income Before Tax |
-$7.00 M |
-$12.73 M |
-$19.52 M |
-$10.89 M |
-$8.59 M |
-$11.63 M |
-$1.14 M |
-$420,200.00 |
-$817,993.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$502.00 |
-$94,077.00 |
-$32,495.00 |
-$76,061.00 |
-$3.48 M |
$367.00 |
$9,643.00 |
$1,264.00 |
| Net Income |
-$7.00 M |
-$12.73 M |
-$19.42 M |
-$10.86 M |
-$8.59 M |
-$11.63 M |
-$1.14 M |
-$420,200.00 |
-$817,993.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-4.92 |
-11.98 |
-26.12 |
-21.79 |
-21.8 |
-61.1 |
-5.2 |
-2.2 |
-4.28 |
| EPS Diluted |
-4.91 |
-11.98 |
-26.12 |
-21.79 |
-21.8 |
-61.1 |
-5.2 |
-2.2 |
-4.28 |
| Weighted Average Shares
Out |
$1.42 M
|
$1.06 M
|
$743,549.00
|
$498,525.00
|
$394,099.00
|
$190,374.00
|
$218,994.00
|
$191,131.00
|
$191,276.00
|
| Weighted Average Shares
Out Diluted |
$1.42 M
|
$1.06 M
|
$743,549.00
|
$498,525.00
|
$394,099.00
|
$190,374.00
|
$218,994.00
|
$191,131.00
|
$191,276.00
|
| Link |
|
|
|
|
|
|
|
|
|
